Disclaimer:
For research use only. Not for human consumption. Intended for laboratory-based studies by qualified professionals. The statements made within this website have not been evaluated by the US Food and Drug Administration. The statements and the products of this company are not intended to diagnose, treat, cure or prevent any disease.
 
Overview:
Tirzepatide is a dual incretin mimetic peptide studied for its potent effects on metabolic regulation, appetite suppression, and insulin sensitivity. It acts as a dual agonist at both the GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptors, offering a next-generation approach to weight managementand glycemic control in metabolic research models.
Mechanism of Action:
Tirzepatide activates two key incretin pathways:
GLP-1 receptor activation promotes insulin secretion, reduces glucagon output, delays gastric emptying, and increases satiety through central nervous system signaling.
GIP receptor activation enhances glucose-dependent insulin release and supports lipid metabolism and energy utilization.
The combination of these pathways has been shown to synergistically improve glucose tolerance, energy expenditure, and body composition, making Tirzepatide one of the most powerful metabolic peptides in current research.
Research Highlights:
Demonstrated substantial reductions in body weight and fat mass in preclinical and clinical models.
Shown to significantly improve insulin sensitivity and glucose metabolism.
Studied for potential cardiovascular and hepatic metabolic benefits.
Represents a major advancement in incretin-based metabolic and obesity research.
Specifications:
Form: Lyophilized powder (research-grade)
Purity: ≥98% (HPLC-tested)
Storage: Store refrigerated (2–8 °C), protected from light and humidity.
Disclaimer:
For research use only. Not for human consumption. Intended exclusively for qualified laboratory professionals conducting controlled metabolic and endocrinological studies.